Genomic Predictors for Radiation Sensitivity and Toxicity in Breast Cancer—from Promise to Reality

Precision medicine and personalized treatment recommendations have become standard for systemic therapy decision-making in women with breast cancer. Until recently, however, such opportunities have been lacking for radiation related treatment decisions. Recent studies have explored the utility of using genomic signatures developed to make systemic therapy recommendations (e.g. Oncotype DX®, ProSigna®, IHC4-C) to guide recommendations for...